JAK/STAT Signaling - Breast Cancer
The JAK (Janus kinase) / STAT (signal transducer and activator of transcription) signaling pathway transduce signals that are essential for development, cellular differentiation and homeostasis. This pathway plays a critical role in cytokine receptor systems, regulating growth, survival and pathogen resistance. JAK is a family of non-receptor protein tyrosine kinases, consisting of JAK1, JAK2, JAK3 and TYK2 (Tyrosine Kinase-2). STATs are transcription factors that activated following recruitment to an activated receptor complex, seven STAT proteins have been identified: STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6.
Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
清除全部
- A8375 AZD8931 (Sapitinib)中文名: 沙普替尼Target: EGFR|ErbBSummary: ErbB抑制剂
- A8366 ARRY-380Target: HER2Summary: 酪氨酸激酶HER2和P95-HER2抑制剂。
- A8322 Neratinib (HKI-272)1 Citation中文名: 来那替尼Target: EGFRSummary: HER2/EGFR抑制剂
- A2224 Stattic5 CitationTarget: STATSummary: STAT3抑制剂
- A2412 CP-724714Target: VEGFR|PDGFR|Bcr-Abl|Src|EGFR|c-MET|Insulin Receptors|IRG-1RSummary: 有效的HER2选择性抑制剂
- A8219 Gefitinib (ZD1839)3 Citation中文名: 吉非替尼Target: EGFRSummary: EGFR抑制剂
- A4512 Cucurbitacin I中文名: 葫芦素 ITarget: STAT|JAKSummary: STAT3/JAK2信号转导抑制剂
- A3433 Gefitinib hydrochloride中文名: 盐酸吉非替尼Target: EGFRSummary: EGFR有效的抑制剂
- A3012 Ruxolitinib (INCB018424)4 Citation中文名: 鲁索替尼Target: JAKSummary: JAK抑制剂